Jump to content
Invision Community
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
META-99 SEARCH ENGINE             CONTACT US

All Activity

This stream auto-updates     

  1. Last week
  2. Earlier
  3. Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030, growing at an annualized rate of over 40%, claims Roots Analysis Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: · A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s). · Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics. · A detailed review of the current market landscape of microbiome diagnostic tests, brief profiles of popular diagnostic developers and indicative list of screening and profiling test kits. · A detailed assessment of the current market landscape of FMT therapies, a geographical clinical trial analysis and information on various stool banks. · A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework. · An analysis of the varied microbiome-focused initiatives of big pharma players. · An analysis of the start-ups / small-sized players engaged in the development of microbiome therapeutics and diagnostics. · An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs. · An analysis of the investments made at various stages of development in start-ups / small-sized companies. · An indicative list of contract manufacturers, in-house manufacturers and CROs that currently claim to have the necessary capabilities. · An assessment of the emerging role of big data highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from in the microbiome research. · An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products · A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) segments: · Type of Therapy (Tx) · Prescription Drug · Prebiotics · Probiotics · Type of Molecule (Tx) · Small Molecules · Biologics · Target Indication (Tx+Dx) · Acne Vulgaris · Atopic Dermatitis · Clostridium difficile Infection · Colorectal Cancer · Crohn’s Disease · Diabetes · Irritable Bowel Syndrome · Lactose Intolerance · Lung Cancer · Nonalcoholic steatohepatitis (NASH) · Obesity · Ulcerative colitis · Therapeutic Area (Tx+Dx) · Autoimmune Disorders · Dental Disorders · Digestive and Gastrointestinal Disorders · Dermatological Disorders · Infectious Disease · Metabolic Disorders · Oncology · Others · Key Geographical Regions (Tx+Dx) · North America · Europe · Asia-Pacific and Rest of the World Key companies covered in the report · 4D Pharma · Armata Pharmaceuticals · Evelo Biosciences · Rebiotix (Acquired by Ferring Pharmaceuticals) · Seres Therapeutics · Vedanta Biosciences For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  4. Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030, claims Roots Analysis Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. In addition to other elements, the study includes: · A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs. · A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations. · Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion). · An analysis of the partnerships that have been established in this domain, in the recent past. · An analysis of the various expansion initiatives undertaken by the players in this domain. · An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain. · A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO. · A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution. · A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain. · A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) · Type of Product · HPAPIs · Highly Potent Finished Dosage Forms · Company Size · Small-sized · Mid-sized · Large / Very Large · Scale of Operation · Preclinical / Clinical · Commercial · Type of Pharmacological Molecule · Small Molecules · Biologics · Type of Highly Potent Finished Dosage Form · Injectables · Oral Solids · Creams · Others · Key geographical regions · North America · Europe · Asia Pacific · Rest of the World The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies: · Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals) · Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics) · Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research) · Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions) · Roberto Margarita (Business Development Director, CordenPharma) · Allison Vavala (Senior Manager, Business Development, Helsinn) · Mark Wright (Site Head, Piramal Healthcare) · Javier E. Aznárez Araiz (Business Development Technician, Idifarma) Key companies covered in the report · AbbVie Contract Manufacturing · CARBOGEN AMCIS · Catalent · Evonik · Formosa Laboratories · Intas · Lonza · MabPlex · Pfizer CentreOne For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  5. The fragment-based drug discovery market is estimated to be worth around USD 1.6 billion by 2030, predicts Roots Analysis Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: · A detailed review of the overall landscape of fragment-based drug discovery library and service providers. · Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). · An analysis of the partnerships that have been established in the recent past. · A detailed analysis on acquisition targets. · An insightful competitiveness analysis of fragment-based drug discovery library and service providers. · An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach. · A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) · Type of Technique · X-ray Crystallography · Nuclear Magnetic Resonance · Surface Plasmon Resonance · Other Screening Techniques · Type of Service · Library Screening · Fragment Screening · Fragment Optimization · End User · Industry Players · Non-Industry Players · Key Geographical Region · North America (US and Canada) · Europe (UK, France, Germany, Spain, Italy, and rest of Europe) · Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world) Key companies covered in the report: · 2bind · Charles River Laboratories · ChemAxon · ComInnex · Creative Biolabs · Creative Biostructure · CRELUX · Domainex · Evotec · Red Glead Discovery · SARomics Biostructures · Shanghai ChemPartner · Sygnature Discovery · Vernalis Research For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  6. Given the cost saving potential across different processes and operations, the cell and advanced therapies supply chain management market is projected to grow at an annualized rate of ~25% rapid till 2030 Roots Analysis has done a detailed study on Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 510+ page report, which features 185+ figures and 400+ tables, please visit this link Key Market Insights Presently, over 160 innovative, software-enabled systems are being used to efficiently manage and streamline various aspects of the complex supply chain of cell and advanced therapies Company involved in this domain are putting in significant efforts to develop advanced software solutions and also differentiate their offerings, from those of other industry players, in order to maintain a competitive edge North America is the major hub of innovation in this field, serving as the base for companies of all sizes, which are primarily engaged in developing cloud-based solutions for diverse applications The cell and advanced therapies market is characterized by an elaborate value chain, involving a multitude of processes and several stakeholders, each having a discrete set of priorities and requirements Increase in partnership activity reflects the growing interest of stakeholders in this industry; over 50% of reported deals were established to deploy software solutions for enhancing visibility and supply chain performance An analysis of recent activity on Twitter reveals the increasing interest and ongoing efforts of industry stakeholders in providing needle-to-needle traceability and supply chain orchestration solutions Given their cost saving potential across different processes and operations, we expect the cell and advanced therapy supply chain solutions market to grow at an annualized rate of around 25% over the next decade In the mid-long term, the projected opportunity is anticipated to be well distributed across various global regions, different end uses / applications and mode of deployment of various proprietary software solutions For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html Table of Contents 3.1. Context and Background 3.2. An Introduction to Cell and Advanced Therapies 3.2.1. Classification of Advanced Therapy Medicinal Products 3.2.2. Current Market Landscape 3.3. Overview of Cell and Advanced Therapies Supply Chain 3.3.1. Donor Eligibility and Selection 3.3.2. Sample Collection 3.3.3. Manufacturing 3.3.4. Logistics 3.3.5. Patient Verification and Treatment 3.3.6. Challenges Associated with the Cell and Advanced Therapies Supply Chain 3.3.6.1. Process Standardization 3.3.6.2. Packaging and Shipping Qualification 3.3.6.3. Validation of Storage Containers 3.3.6.4. Process Qualification 3.3.6.5. Chain of Custody Documentation 3.3.6.6. Demand Forecastin 3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management 3.4.1. Enterprise Manufacturing System 3.4.2. Laboratory Information Management System 3.4.3. Inventory Management System 3.4.4. Quality Management System 3.4.5. Logistics Management System 3.4.6. Patient Management System 3.4.7. Electronic Clinical Outcome Assessments System 3.4.8. Supply Chain Orchestration Platfor 3.5. Growth Drivers and Roadblocks 3.6. Recent Developments and Upcoming Trends 3.6.1. Blockchain Technology 3.6.2. Internet of Things 3.6.3. Augmented Reality 3.6.4. Big Data Analytics 3.6.5. Artificial Intelligence 4. CURRENT MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape 4.2.1. Analysis by Type of Software Solution 4.2.2. Analysis by Key Specification and Benefits Offered 4.2.3. Analysis by Application 4.2.4. Analysis by Mode of Deployment 4.2.5. Analysis by Scale of Management 4.2.6. Analysis by Regulatory Certifications / Accreditations 4.2.7. Analysis by End User 4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Location of Headquarters 4.3.3. Analysis by Company Size 4.3.4. Analysis by Support Services Offered 4.3.5. Leading Developers: Analysis by Number of Software Solutions 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Methodology 5.3. Assumptions and Key Input Parameters 5.4. Competitiveness Analysis: Software Solution Providers 5.4.1. COP Developers 5.4.2. EMS Developers 5.4.3. IMS Developers 5.4.4. LIMS Developers 5.4.5. LMS Developers 5.4.6. PMS Developers 5.4.7. QMS Developers 5.4.8. TTS Developers 6. CELL AND ADVANCED THERAPIES SUPPLY CHAIN MANAGEMENT: COMPANY PROFILES 6.1. Chapter Overview 6.2. Brooks Life Sciences 6.2.1. Company Overview 6.2.2. Supply Chain Management Software Solution Portfolio 6.2.3. Recent Developments and Future Outlook 6.3. Cryoport 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. Supply Chain Management Software Solution Portfolio 6.3.4. Recent Developments and Future Outlook 6.4. MasterControl 6.4.1. Company Overview 6.4.2. Supply Chain Management Software Solution Portfolio 6.4.3. Recent Developments and Future Outlook 6.5. SAP 6.5.1. Company Overview 6.5.2. Supply Chain Management Software Solution Portfolio 6.5.3. Recent Developments and Future Outlook 6.6. Savsu Technologies 6.6.1. Company Overview 6.6.2. Financial Information 6.6.3. Supply Chain Management Software Solution Portfolio 6.6.4. Recent Development and Future Outlook 6.7. TraceLink 6.7.1. Company Overview 6.7.2. Financial Information 6.7.3. Supply Chain Management Software Solution Portfolio 6.7.4. Recent Developments and Future Outlook 7. SUPPLY CHAIN ORCHESTRATION PLATFORM: EMERGING TRENDS AND KEY Players 7.1. Chapter Overview 7.2. Supply Chain Orchestration Platforms 7.2.1. Key Functions of Supply Chain Orchestration Platforms 7.2.2. Advantages of Supply Chain Orchestration Platforms 7.2.3. Supply Chain Orchestration Platform Implementation Strategies 7.2.3.1. Building the Required Foundation 7.2.3.2. Incorporating an Appropriate Scheduling System 7.2.3.3. Integration with Core Systems / Processe 7.3. Supply Chain Orchestration Platform: Social Media Trends 7.3.1. Scope and Methodology 7.3.2. Historical Trends in Volume of Tweets 7.3.3. Popular Keyword 7.4. Key Industry Players 7.4.1. Be The Match BioTherapies® 7.4.1.1. Company Overview 7.4.1.2. Financial Information 7.4.1.3. MatchSource®: Software Description 7.4.1.4. Recent Developments and Future Outloo 7.4.2. Clarkston Consulting 7.4.2.1. Company Overview 7.4.2.2. Cell Therapy Orchestration Platform: Software Description 7.4.2.3. Recent Developments and Future Outloo 7.4.3. Haemonetics 7.4.3.1. Company Overview 7.4.3.2. Financial Information 7.4.3.3. EdgeCell®: Software Description 7.4.3.4. Recent Developments and Future Outlook 7.4.4. Hypertrust Patient Data Care 7.4.4.1. Company Overview 7.4.4.2. Hypertrust X-Chain: Software Description 7.4.4.3. Recent Developments and Future Outloo 7.4.5. Lykan Bioscience 7.4.5.1. Company Overview 7.4.5.2. Unnamed Software: Software Description 7.4.5.3. Recent Developments and Future Outlook 7.4.6. MAK-SYSTEM 7.4.6.1. Company Overview 7.4.6.2. T.C.S.: Software Description 7.4.6.3. Recent Developments and Future Outlook 7.4.7. sedApta 7.4.7.1. Company Overview 7.4.7.2. O.S.A.: Software Description 7.4.7.3. Recent Developments and Future Outlook 7.4.8. Stafa Cellular Therapy 7.4.8.1. Company Overview 7.4.8.2. Stafa Cellular Therapy Lab: Software Description 7.4.8.3. Recent Developments and Future Outlook 7.4.9. Title 21 Health Solutions 7.4.9.1. Company Overview 7.4.9.2. Cell Therapy Software: Software Description 7.4.9.3. Recent Developments and Future Outlook 7.4.10. TrakCel 7.4.10.1. Company Overview 7.4.10.2. Financial Information 7.4.10.3. Cell Orchestration Platform: Software Description 7.4.10.4. Recent Developments and Future Outlook 7.4.11. Vineti 7.4.11.1. Company Overview 7.4.11.2. Financial Information 7.4.11.3. Personalized Therapy Management Platform: Software Description 7.4.11.4. Recent Developments and Future Outlook 8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Types of Funding 8.3. Cell and Advanced Therapies Supply Chain Management: Funding and Investment Analysis 8.3.1. Analysis by Number of Funding Instances 8.3.2. Analysis by Amount Invested 8.3.3. Analysis by Type of Funding 8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions 8.3.5. Most Active Players: Analysis by Number of Funding Instances 8.3.6. Most Active Investors: Analysis by Number of Funding Instances 8.3.7. Geographical Analysis by Amount Invested 8.4. Concluding Remarks 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships 9.3.1. Analysis by Year of Partnership 9.3.2. Analysis by Type of Partnership 9.3.3. Partner’s Focus Area 9.3.3.1. Analysis by Partner’s Focus Area 9.3.3.2. Analysis by Type of Platform and Partner’s Focus Area 9.3.3.3. Analysis by Type of Partnership Model and Partner’s Focus Area 9.3.4. Software Solution Analysis 9.3.4.1. Analysis by Type of Software Solutions 9.3.4.2. Analysis by Type of Platform and Partnership Model 9.3.5. Most Active Players: Analysis by Number of Partnerships 9.3.6. Geographical Analysis 9.3.6.1. Most Active Players 9.3.6.2. Intercontinental and Intracontinental Agreements 10. SUPPLY CHAIN UTILIZATION USE CASES 10.1. Chapter Overview 10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases 10.2.1. Analysis by Year of Utilization 10.2.2. Analysis by Type of Partner 10.2.2.1. Most Active Users: Distribution by Number of Platform Utilization Instances 10.2.2.2. Geographical Distribution of Users 10.2.3. Analysis by Type of Software Solution 10.2.4. Most Active Players: Analysis by Number of Platform Utilization Agreements 10.2.5. Most Active Players: Regional Analysis by Number of Platform Utilization Agreements 10.2.5.1. Regional Distribution by Type of Software Solutions 10.2.5.2. Intercontinental and Intracontinental Agreements 11. STAKEHOLDER NEEDS ANALYSIS 11.1. Chapter Overview 11.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders 11.2.1. Comparison of Stakeholder Needs 12. COST SAVINGS ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Methodology 12.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 12.3.1. Cost Saving Potential in Sample Collection and Processing, 2019-2030 12.3.2. Cost Saving Potential in Manufacturing, 2019-2030 12.3.3. Cost Saving Potential in Logistics, 2019-2030 12.3.4. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 13. MARKET FORECAST 13.1. Chapter Overview 13.2. Key Assumptions and Forecast Methodology 13.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030 13.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application 13.3.1.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030 13.3.1.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for, Manufacturing, 2019-2030 13.3.1.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for, Logistics, 2019-2030 13.3.1.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 13.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User 13.3.2.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030 13.3.2.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs / Commercial Organizations, 2019-2030 13.3.2.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals / Medical Centers, 2019-2030 13.3.2.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030 13.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution 13.3.3.1. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.2. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.3. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.4. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.5. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.6. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.3.7. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 13.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment 13.3.4.1. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030 13.3.4.2. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030 13.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Scale of Operation 13.3.5.1. Cell and Advanced Therapies Supply Chain Management Market for Clinical Therapies, 2019-2030 13.3.5.2. Cell and Advanced Therapies Supply Chain Management Market for Commercial Therapies, 2019-2030 13.3.6. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography 13.3.6.1. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030 13.3.6.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030 13.3.6.3. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030 13.3.6.4. Cell and Advanced Therapies Supply Chain Management Solutions Market in Rest of the World, 2019-2030 13.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment 13.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030 13.4.1.1. Cell Orchestration Platforms Market for Sample Collection and Processing, 2019-2030 13.4.1.1.1. Cell Orchestration Platforms Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.1.2. Cell Orchestration Platforms Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.2. Enterprise Manufacturing Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.2.1. Enterprise Manufacturing Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.2.2. Enterprise Manufacturing Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.3. Inventory Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.3.1. Inventory Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.3.2. Inventory Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.4. Laboratory Information Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.4.1. Laboratory Information Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.4.2. Laboratory Information Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.5. Logistics Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.5.1. Logistics Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.5.2. Logistics Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.6. Patient Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.6.1. Patient Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.6.2. Patient Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.1.7. Quality Management Systems Market for Sample Collection and Processing, 2019-2030 13.4.1.7.1. Quality Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030 13.4.1.7.2. Quality Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030 13.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030 13.4.2.1. Cell Orchestration Platforms Systems Market for Manufacturing, 2019-2030 13.4.2.1.1. Cell Orchestration Platforms Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.1.2. Cell Orchestration Platforms Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.2. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030 13.4.2.2.1. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.2.2. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.3. Inventory Management Systems Market for Manufacturing, 2019-2030 13.4.2.3.1. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.3.2. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.4. Laboratory Information Management Systems Market for Manufacturing, 2019-2030 13.4.2.4.1. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.4.2. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.5. Logistics Management Systems Market for Manufacturing, 2019-2030 13.4.2.5.1. Logistics Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.5.2. Logistics Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.6. Patient Management Systems Market for Manufacturing, 2019-2030 13.4.2.6.1. Patient Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.6.2. Patient Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.2.7. Quality Management Systems Market for Manufacturing, 2019-2030 13.4.2.7.1. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 13.4.2.7.2. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 13.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030 13.4.3.1. Cell Orchestration Platforms Market for Logistics, 2019-2030 13.4.3.1.1. Cell Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.1.2. Cell Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.2. Enterprise Manufacturing Systems Market for Logistics, 2019-2030 13.4.3.2.1. Enterprise Manufacturing Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.2.2. Enterprise Manufacturing Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.3. Inventory Management Systems Market for Logistics, 2019-2030 13.4.3.3.1. Inventory Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.3.2. Inventory Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.4. Laboratory Information Management Systems Market for Logistics, 2019-2030 13.4.3.4.1. Laboratory Information Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.4.2. Laboratory Information Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.5. Logistics Management Systems Market for Logistics, 2019-2030 13.4.3.5.1. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.5.2. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.3.6. Patient Management Systems Market for Logistics, 2019-2030 13.4.3.6.1. Patient Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 13.4.3.6.2. Patient Management Systems Market for Logistics: On-premises Solutions, 2019-2030 13.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.1. Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.1.1. Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 13.4.4.1.2. Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 13.4.4.2. Inventory Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.2.1. Inventory Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 13.4.4.2.2. Inventory Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 13.4.4.3. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 13.4.4.3.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 13.4.4.3.2. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 14. EXECUTIVE INSIGHTS 14.1. Chapter Overview 14.2. Thermo Fisher Scientific 14.2.1. Company Snapshot 14.2.2. Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy 14.3. Cell and Gene Therapy Catapult 14.3.1. Company Snapshot 14.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer 14.4. McKesson 14.4.1. Company Snapshot 14.4.2. Interview Transcript: Divya Iyer, Senior Director, Corporate Strategy and Business Development, and Jill Maddux, Director, Cell and Gene Therapy Product Strategy 14.5. TrakCel 14.5.1. Company Snapshot 14.5.2. Interview Transcript: Martin Lamb, Former Chief Business Officer 15. CONCLUDING REMARKS 15.1. Chapter Overview 15.2. Key Takeaways 16. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS 17. APPENDIX 2: TABULATED DATA 18. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS Contact Details Gaurav Chaudhary +1 (415) 800 3415 gaurav.chaudhary@rootsanalysis.com
  7. 1. Giovanni's Room, by James Baldwin Author Chavisa Woods is far from alone when calling Giovanni’s Room “masterfully written, heartbreaking.” It’s a book that has resonated with so many queer people since first being published in 1956, speaking to issues of identity even now. Woods, a Lambda :Literary Award nominee for her novel Things to Do When You’re Goth in the Country, says Baldwin succeeded at “blurring the lines of hero and villain and bringing the complexity of human nature into horrifying focus.” Maybe that’s because Baldwin said the book isn’t actually about being gay. “Giovanni’s Room is not really about homosexuality,” said Baldwin in a 1980 interview about queer life. “It’s the vehicle through which the book moves. Go Tell It on the Mountain, for example, is not about a church, and Giovanni is not really about homosexuality. It’s about what happens to you if you’re afraid to love anybody.” 2. The Color Purple, by Alice Walker A revelation when it was published in 1982, Alice Walker’s novel delves into the intersections of race, gender, family, and sexuality in Georgia circa 1930. For all of the painful physical and sexual abuse and heartache Walker’s protagonist Celie endures at the hands of Mister, the man she’s forced to marry as an adolescent, and the violent, institutionalized racism she faces as a woman of color, the novel teems with hope and light. Epic in scope, the novel is, in part, a story of love between women —Celie’s love for her long-lost sister Nettie and for Shug Avery, the blues singer and former lover of Mister’s Celie falls for and with whom she eventually makes a home. "An epic tale of perseverance and empowerment as well as a celebration of love in all its forms," Tailor-Made author Yolanda Wallac, said of the novel. Of Walker's masterpiece, Long Shadows author Kate Sherwood said, "I loved how the characters found hope (and love) despite everything standing in their way." Steven Spielberg directed the 1985 adaptation of the film that starred Whoopi Goldberg, Danny Glover, and Oprah Winfrey and earned several Oscar nominations. 3. The Price of Salt, by Patricia Highsmith On the heels of her successful debut novel Strangers on a Train (with its own intimations of queerness), an encounter Patricia Highsmith had with a New Jersey socialite while working at a shopgirl at a department store became the seed for 1952’s The Price of Salt. The result, which Highsmith’s publisher forced her to publish under the pseudonym Claire Morgan at a time when a bold depiction of desire between women that eschewed the requisite tragic ending for those who transgressed could have tanked her career, would become that rare example of a lesbian-themed novel with what would prove to be a radically hopeful ending. "A novel that is simultaneously of its time and timeless, and it holds the distinction of being the first of its kind to have a happy ending," Yolanda Wallace said of the novel. SJ Sindu, author of Marriage of a Thousand Lies, called it, "One of the first Anglophone works to challenge the trope of the sad/suicidal gays who die at the end, this book gave us a blueprint of what queer fiction could look like." The Price of Salt's dizzyingly erotically charged prose also telegraphed her signature sense of an ominous "menace" (in this case, the threat of being caught or found out just as the Red Scare hit the United States). Highsmith went on to write more queer-tinged fiction, including The Talented Mr. Ripley and all of the Ripley novels to follow. The Price of Salt, of course, became the critically acclaimed Todd Haynes-helmed 2015 film Carol ,starring Cate Blanchett and Rooney Mara. advocate.com
  8. 4. Orlando, by Virginia Woolf Orlando, which Virginia Woolf wrote in tribute to friend and lover Vita Sackbville-West, is a study in gender fluidity across time and space. The eponymous protagonist starts as a rakish young nobleman in Elizabethan England, finding favor with the queen, then falling out with her and indulging liberally in sex with a variety of women but having an intense friendship with a male poet. Later Orlando is sent on a diplomatic mission to Constantinople, where he finds he's become a woman, and the gender switch offers an opportunity for commentary on the limitations society places on women. The book ends in 1928, with Orlando still a woman, with a husband and children but also a new sense of possibility, as this is the year women won full voting rights in England. And while the novel's action spans more than 300 years, Orlando ages only 36. A well-received 1992 film version, directed by Sally Potter, featured Tilda Swinton and Quentin Crisp. 5. Maurice, by E.M. Forster Although the great E.M. Forster (A Passage to India, A Room With a View, Howards End) wrote the benchmark gay novel Maurice circa 1913, it was published posthumously in 1971. In a lush tale of manners, position, and desire, the titular character meets and falls for his classmate Clive while at Oxford. The pair embark on a two-year affair until Clive leaves Maurice to marry a woman and live out his proscribed life as part of the landed gentry, leaving Maurice in shambles and seeking to cure his homosexuality. But Forster’s novel does not end in gay tragedy. Maurice falls in love with another man, Alec Scudder, and finally abandons his station so that they can be together. The author of Night Drop, Marshall Thornton called the novel "the original gay romance." A note found on Forster’s manuscript for Maurice, which was discovered tucked in a drawer, read “Publishable, but worth it?” Ismail Merchant and James Ivory adapted the novel to the big screen in a gorgeous film starring James Wilby, Hugh Grant, and Rupert Graves. 6. Middlesex, by Jeffrey Eugenides Jeffrey Eugenides won the Pulitzer Prize for his 2002 coming-of-age story about intersex protagonist Cal Stephanides. Inspired by the 19th-century memoirs of Herculine Barbin, Middlesex incorporates elements of Greek mythology as well as Eugenides’s Greek-American upbringing to tell a groundbreaking story about gender identity in the 21st century. While Middlesex has received some criticism from the intersex community — the author does not identify as intersex, nor did he consult with those who do — the novel is undoubtedly a landmark in queer visibility. In some literary circles, it is considered a candidate for the title of the Great American Novel. advocate.com
  9. 7. The Line of Beauty, by Alan Hollinghurst Alan Hollinghurst famously questioned the future of the gay novel this year, which is striking since he's often viewed as helping make queer books accessible to a mainstream audience. His 2004 novel broke through in a major way — The Line of Beauty won that year's prestigious Man Booker Prize for fiction. Hollinghurt was praised for his expert command of the English language and his flawless re-creation of upper-class British society and conservative political circles of the 1980s. Hollinghurst set his pen on the sexual hypocrisies of homophobic politicians, many of whom had their own indiscretions behind closed doors. The book follows Nick Guest, a gay graduate student unofficially adopted by the family of a schoolmate. Nick gets a sneak peek at the aristocracy, while indulging in no shortage of sex and party favors; the fun comes to a crashing halt as AIDS enters the fray. Amid all the human drama, there's an amusing and memorable cameo from the Iron Lady. "Captures a vitally important era in lovely prose" is how Night Drop's Marshall Thornton describes Hollinghurst's most acclaimed book. 8. Rubyfruit Jungle, by Rita Mae Brown Many queer female writers see Rita Mae Brown's 1973 coming-of-age book as an iconic work of LGBT literature: "[I love Rubyfruit Jungle] because, well, because. I think this was the first 'lesbian' book I ever read! And devoured. And loved," writes The Year of Needy Girls' Patricia Smith. Yolanda Wallace, author of Tailor-Made, tells us, "When I was a teenager questioning my sexuality, this book provided the answers I was looking for." Semi-autobiographical, Rubyfruit Jungle follows Molly Bolt's amorous adventures from childhood to adulthood, including a stint in swinging New York City. While Molly has sexual adventures with men, her true love is women, and Brown never shies away from describing Molly's insatiable passion for the ladies (the title perfectly captures Molly's zeal for female anatomy). Now assigned in many queer literature courses, Rubyfruit Jungle is brazen and brave; its frank discussion of lesbian sexuality can seem shocking to modern readers who imagine life in the early 1970s was less raunchy. Rubyfruit Jungle is a page-turning reminder that queer lust and queer sex are timeless. 9. Zami, by Audre Lorde "She calls it a biomythography and leads us through a heart-wrenching account of the black lesbian experience." – SJ Sindu, Lambda Literary Award for Lesbian Fiction Winner This 1982 autobiography by the iconic queer black poet Audre Lorde is an experience of intersectionality, in a genre of intersections. Lorde classified it as biomythography, which combines history, biography, and myth. A fierce love letter to the strength women have given her throughout her upbringing, the book explores her challenges growing up blind in 1930s Harlem, fighting for dignity in the heat of Jim Crow, and finding a voice in the New York City lesbian bar scene. While books like The Price of Salt show lesbians walking away from motherhood, Zami celebrates the beauty of when mothers stay through the harshest of challenges. advocate.com
  10. 10. A Single Man, by Christopher Isherwood A quietly devastating exploration of love, loneliness, and the often-crushing weight of adult responsibilities, 1962's A Single Man might just be one of Isherwood's most beloved works. The short novel — under 200 pages — tracks the experiences of an aging college professor in Los Angeles. Wracked with depression over the loss of his partner in a car accident, George matter-of-factly plots his suicide. But, as Isherwood demonstrates, life gets in the way. After crashing into others who are suffering as much as he is, George has a change of heart. But a last-minute twist changes everything. While Tom Ford's 2009 film adaptation conveys the styles and anxieties of the early 1960s, it doesn't exactly capture the beautiful tone of despondency created by the incomparable Isherwood. 11. The City and the Pillar, by Gore Vidal The City and the Pillar shocked America when it was released in 1948. The queer coming-of-age novel about Jim Willard and his search for love was the first novel from a respected writer (Gore Vidal) to speak directly and sympathetically about the gay experience in an era when homosexuality was still very much taboo. The book is remembered today for this legacy as well as for various themes — Hollywood’s glass closet, being gay in the military, the poisonous effects of homophobia on society — that still reverberate today. 12. The Picture of Dorian Gray, by Oscar Wilde The only novel by the great Oscar Wilde may not be overtly gay, but there’s plenty of gay subtext there for the careful reader – about as much gay subtext as a popular author could get away with in 1891. Dorian’s friends Basil Hallward and Lord Henry Wotton express intense admiration for his beauty, and passages that show Basil’s feelings for Dorian as more clearly homoerotic were excised by an editor, according to Nicholas Frankel, who edited an edition presenting Wilde’s original text in 2011. Even the text as originally published has references to Dorian’s corruption of not only young women but young men: “There was that wretched boy in the Guards who committed suicide. You were his great friend,” Basil tells Dorian at one point. “There was Sir Henry Ashton, who had to leave England, with a tarnished name. You and he were inseparable.” “At the Wilde trials of 1895, the opposing attorneys read aloud from ‘Dorian Gray,’ calling it a ‘sodomitical’ book,” Alex Ross wrote in The New Yorker in 2011. “Wilde went to prison not because he loved young men but because he flaunted that love, and ‘Dorian Gray’ became the chief exhibit of his shamelessness.” advocate.com
  11. 13. City of Night by John Rechy City of Night, a 1963 novel by John Rechy, is a seminal piece of fiction that follows the life of a gay hustler in New York City, Los Angeles, New Orleans, and San Francisco. Through stream-of-consciousness narration, the reader gets a glimpse of queer life in mid-century America, with a long and fascinating cast of characters that includes drag performers, S&M practitioners, and sex workers. The book has inspired music from the Doors as well as a film by Gus Van Sant, My Own Private Idaho. "This epic chronicle of gay culture in the American sixties is as far-reaching as it is important, giving us a glimpse into identity and motive,” affirmed SJ Sindu, the author of Marriage of a Thousand Lies. 14. Stone Butch Blues, by Leslie Feinberg Well ahead of its time, Leslie Feinberg’s 1993 Stone Butch Blues, about Jess Goldberg, a butch working-class lesbian, took massive strides in breaking down the gender binary. A story that is both hopeful in Jess’s determination to forge an identity and heartrending in its depiction of violence against her for her daring to be herself, Stone Butch Blues endures as essential to the queer canon. Feinberg, whose bio reads “writer and transgender activist,” would in later years become known more for activism, but the landmark novel about Jess’s refusal to fit into a prescribed box for gender is arguably Feinberg’s legacy. 15. Tales of the City, by Armistead Maupin Gay literature was forever changed the day Mary Ann Singleton first met her transgender landlady, Anna Madrigal, when she moved to San Francisco's 28 Barbary Lane. What began as serialized stories in the San Francisco Chronicle by writer Armistead Maupin became a 1978 novel. It was followed by a Tales of the City series of books, which chronicled decades of queer life in the Golden Gate City, including the AIDS crisis. Tales of the City was adapted in 1993 into a PBS television miniseries, which starred Laura Linney and Olympia Dukakis. The pair are set to reprise their roles in an upcoming Netflix adaptation, proving the enduring power of Maupin's words. advocate.com
  12. 16. A Boy’s Own Story, by Edmund White A Boy’s Own Story is comparable to another literary classic, J.D. Salinger’s The Catcher in the Rye. The 1982 book by Edmund White, which begins with the first sexual encounter of a 15-year-old boy, is based on his own experiences coming to terms with his gay identity as a youth in the Midwestern United States. White would later write two additional novels, The Beautiful Room Is Empty (1988) and The Farewell Symphony (1997), which follow his gay protagonist into young adulthood. Together, they form a poignant trilogy that chronicles a gay life in the latter half of the 20th century. 17. Well of Loneliness, by Radclyffe Hall Integral to the lesbian canon (despite its being considered somewhat problematic) British writer Radclyffe Hall’s 1928 novel focuses on Stephen Gordon, an upper-class lesbian who dons men’s clothing and becomes a novelist who eventually becomes a part of a literary salon in Paris at a time when there were no overt laws expressly barring homosexuality. Hall’s novel was groundbreaking in her introduction of the views of “sexologists” Richard von Krafft-Ebing and Havelock Ellis, who posited that homosexuality was an inborn, unalterable trait that was considered a congenital sexual inversion that simply meant a “difference” and not a defect. The novel also stood trial on obscenity charges both in the United Kingdom where the book was deemed obscene and ordered destroyed, and in the United States, where it was eventually banned. advocate.com
  13. 18. Fun Home, by Allison Bechdel You might not expect to see a graphic novel in this list, but iconic cartoonist (and Bechdel test namesake) Alison Bechdel always takes the less traveled road. Off the success of her comic strip Dykes to Watch Out For, she created the deeply personal Fun Home: A Family Tragicomic, which touches on her dysfunctional relationship with her father through a lesbian lens. Chronicling Bechdel's confusing childhood in rural Pennsylvania, the book took seven years to create in Bechdel's laborious artistic process, which included photographing herself in poses that are drawn into each human figure. This queer exploration of broken family, unraveling emotions, and suicide was a New York Times best seller, and snagged nominations for the National Book Critics Circle Award and three Eisner Awards – becoming a mainstream critical and commercial success. The book was adapted into a musical, which was a finalist for the Pulitzer Prize for Drama. When it hit Broadway in 2015, it won the Tony Award for Best Musical. 19. Death in Venice, by Thomas Mann Some might say Death in Venice is not necessarily a gay novel, since there is no overt same-sex coupling or coitus. Others might say it's about a man with pedophilic tendencies. Then others might say it's brilliant. German writer Thomas Mann crafted this novella based on his own experience in Venice, where he caught sight of a handsome young man who captivated him, body and soul. Is Aschenbach, the 50-something protagonist, just fixated on beautiful objects, where human beings and centuries-old buildings are of equal lure? Or is it something more lustful and disturbing? It's difficult, in 2018, to divorce the rich subject of sexual desire from the fact that it revolves around a 14-year-old boy. But the novella's legacy endures, amd it serves as an important artifact of secret desire at the turn of the 20th century. advocate.com
  14. 20. Under the Udala Trees, by Chinelo Okparanta "This lyrical book is a wonderful story with a background of a civil war and a love story between two young girls on the frontlines. Wonderful book," gay refugee activist and columnist Danny Ramadan raves about the global-minded story. The book unpacks the emotional life of a young girl displaced by the Nigerian civil war who begins a gut-wrenching affair with a fellow refugee. These girls are from different ethnic communities, forcing them to face not only the taboos of being queer but the prejudices of surviving in a nation that is eating itself alive. "A great recollection of everything anyone would say in Nigeria against homosexuality using the defense of religion," explains David Nnanna Ikpo, the Nigerian author of Fimisile Forever. 21. Oranges Are Not the Only Fruit, by Jeanette Winterson Jeanette Winterson’s first novel, published in 1985, is a semiautobiographical coming-of-age story about a girl growing up in a Pentecostal family in England’s industrial Midlands region. Winterson captures the weirdness of religious zealotry with the authority of someone who’s lived in this environment, and her portrayal of the young woman’s burgeoning lesbian sexuality – problematic in the Pentecostal world – rings true as well. Quirky and memorable secondary characters further enhance the novel, which made Winterson a literary star overnight, esteemed by both readers and fellow authors. “A beautiful piece of fiction, this novel takes us through the complicated relationship between religion and LGBTQ+ identity.”, says SJ Sindu, the prize-winning author of Marriage of a Thousand Lies. advocate.com
  15. 22. The Hours, by Michael Cunningham Cunningham’s 1998 novel, winner of the Pulitzer Prize and the PEN/Faulkner Award, tells three parallel stories involving queer characters in different times and places. In England in the 1920s, Virginia Woolf struggles with depression and writing Mrs. Dalloway, a novel to which Cunningham pays homage; in mid-20th-century Los Angeles, housewife Laura Brown, discontented with her life, confronts her attraction to women; and in 1990s New York City, Clarissa Vaughan, who is lesbian, plans a party for her best friend, writer Richard Brown, a gay man dying of AIDS. Cunningham weaves their stories together seamlessly and movingly in a novel that is deservedly recognized as a modern classic. The 2002 film adaptation, written by David Hare and directed by Stephen Daldry, received several Oscar nominations, and Nicole Kidman won Best Actress for her portrayal of Woolf. It costarred Julianne Moore, Meryl Streep, and Ed Harris. 23. A Little Life, by Hanya Yanagihara In 2015, when the novel was published, reviewer and author Garth Greenwell declared in The Atlantic, “A Little Life: The Great Gay Novel Might Be Here.” Hanya Yanagihara’s story of four friends — Jude, Malcolm, JB, and Willem — lasts over 700 pages as you witness the evolution of friendship and love between these men who met in college. We follow them for three decades, withstanding alongside them the waves of trauma that life so often sends. The friends survive together, as described in intensely vulnerable detail. Yanagihara talked with The Guardian about friendship and hardship. “We might all have had that feeling: as a friend, what is my responsibility to save someone who doesn’t want to be saved? Or tell someone to keep living when they don’t want to live?” Gay men are often blindsided by A Little Life’s penetrating clarity about what binds them or drives them apart. advocate.com
  16. 24. Tipping the Velvet, by Sarah Waters Sarah Waters’s 1998 page-turner is the coming-of-age story of Nan, a Whitstable “oyster girl” (talk about a euphemism) circa 1890 who, upon taking in a show in her local theater, becomes smitten with the charismatic masher (male impersonator) Kitty. Waters’s heroine follows Kitty to London, where the more experienced woman schools Nan in the ways of impersonating a dapper dandy onstage. The pair begin performing as men together and become the toast of London’s music halls while simultaneously falling in love. Heartbreak eventually ensues and Nan is left to her own defenses on the streets in the big city. She dabbles in sex work to survive before she becomes a boy-toy for a wealthy older lesbian renowned for throwing Bacchanalian gatherings of women. Finally, though, without the trappings of a male alter ego, Nan comes into her own. The book, an immediate smash with queer women for its frank depiction of lesbian desire and of flirting with gender roles, was made into a 2002 BBC miniseries that reinvigorated interest in the novel, which won the Lambda Literary Award and earned a place on the New York Times list of notable books the year it was published. "Love the sensuousness of it, the unapologetic portrayal of Nan—the sex scenes," said Patty Smith, author of The Year of Needy Girls. 25. Faggots, by Larry Kramer Larry Kramer, a founder of ACT UP and the playwright of The Normal Heart, may be known for his vocal AIDS activism. But his 1978 novel, Faggots, was also a loud statement that portrayed the hedonism of gay New York City. The book features a cast of dozens of gay men, who variously engage in bathhouse orgies, use a slew of party drugs, and cavort in clubs with names like The Toilet Bowl and Fire Island. The book was condemned by numerous LGBT people upon its release for what many perceived as sex-negativity. But the ensuing AIDS crisis established Faggots as a bellwether of the storm to come. advocate.com
  17. Critics of the suppression of gay identity often conclude that, as homosexuality is normalized in broader culture, it will be in video games as well. A 2006 survey exploring gay gamers was the first academic study of any gamer group. With about 10,000 respondents, the survey exhibited a reverse bell curve of gamer sexuality, with most people identifying as either completely heterosexual or homosexual. A 2009 academic paper explored the cultural production of LGBT representation in video games and found that factors that would lead to a significant increase in LGBT content included: the presence of motivated producers in the industry (those that are personally, politically, or commercially interested in LGBT content), how the audience for a text or medium is constructed (what the public backlash from both the LGBT community and conservative groups will be, as well as industry-based reprisals in the form of censorship or ratings), the structure of the industry and how it is funded, and how homosexuality, bisexuality, or transgender identities can be represented in the medium. wikipedia.org
  1. Load more activity
×
×
  • Create New...